Technology
Health
Medical

Verona Pharma

392

$4.04
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.06 (-1.53%) Today
+$0.17 (+4.39%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Verona Pharma and other stocks, options, ETFs, and crypto commission-free!

About VRNA

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. Read More The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

CEO
David S. Zaccardelli
Employees
25
Headquarters
London, Greater London
Founded
2005
Market Cap
51.38M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
43.10K
High Today
$4.16
Low Today
$3.90
Open Price
$3.90
Volume
15.00K
52 Week High
$12.89
52 Week Low
$2.01

Collections

Technology
Health
Medical
Biopharmaceutical
Therapy
Pharmaceutical
2017 IPO
UK

VRNA News

BenzingaApr 8

Update on AGM Procedure

LONDON, April 08, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical com
3

VRNA Earnings

-$1.09
-$0.73
-$0.36
$0.00
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
— per share
Actual
Expected May 5, Pre-Market

People Also Bought

Onconova Therapeutics

26,822

$0.30

+2.01%

Onconova Therapeutics

26,822

$0.30

+2.01%

Advaxis

11,748

$0.68

-2.58%

Agile Therapeutics

20,718

$2.18

+14.74%

Inovio

232,934

$8.14

-2.16%

You May Also Like

FI
CMC
TROV
AAMC
BSMM
ATNM
HPR
PCRFY
IQM
NGD
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.

Buy VRNA

Market Price$4.04
Commissions$0.00
Estimated Cost
$0.00
Sign up for a Robinhood Account to buy or sell Verona Pharma stock and options commission-free.
Search
LearnBlogCareersHelpLog InSign Up